INCYTE COVID-19 Response

Updated June 11, 2021

Incyte takes public health very seriously, and we are closely monitoring the evolving COVID-19 pandemic. Our primary focus is on ensuring patients have access to the medicines they need while safeguarding the health and safety of our employees.

See our responses to frequently asked questions below regarding how Incyte is responding to COVID-19. Please contact our support resources, listed below, for more information.

 

Incyte Medicines

What if I have questions regarding my prescription medicines?
Close
Open

We encourage patients to first discuss any questions or concerns regarding their existing treatments with their healthcare providers, as they are best informed about the specific healthcare needs of their patients and the potential risks associated with discontinuing or modifying treatment.

In the United States, patients with questions can contact Incyte’s U.S. Medical Information line at 1-855-4MED-INFO (1-855-463-3463) or send an email to medinfo@Incyte.com.

Outside the United States patients can call +800-0002-7423 or send an email to globalmedinfo@incyte.com or eumedinfo@incyte.com.

Eligible patients in the United States who are currently prescribed Jakafi® (ruxolitinib) or Pemazyre® (pemigatinib) can contact IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering patient support, including financial assistance and ongoing education and resources for eligible patients.

More information about IncyteCARES is available by visiting www.incytecares.com or calling 1-855-4-Jakafi (855-452-5234).

Eligible patients in the United States who are currently prescribed Monjuvi® (tafasitamab-cxix) can contact My Mission Support, a robust patient support program offering financial assistance, ongoing education and other resources. For more information, please visit My Mission Support

 
I am currently participating in an Incyte clinical trial, will that be impacted by COVID-19?
Close
Open

We are focused on ensuring all patients have access to the medicines they need, including clinical trial participants.

At present, our clinical trials around the world are proceeding and we are working closely with our study sites and vendor partners on continuity of investigational product supply, and conducting and monitoring the studies in accordance with existing and emerging Good Clinical Practice (GCP) guidance from global regulatory agencies. We are preparing contingency plans including notifying relevant stakeholders should that be needed. Study participants can contact their healthcare provider for more information.

Are any Incyte medicines being studied for treatment of COVID-19?
Close
Open

Yes, ruxolitinib has been studied in patients with COVID-19.

DEVENT

  • In March 2021, we announced results from the Phase 3 DEVENT study evaluating the efficacy and safety of ruxolitinib (5mg and 15mg) plus standard of care (SoC) versus SoC in patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs, with disease severity requiring mechanical ventilation. Improvement in mortality for each dose compared to placebo (primary endpoint), while trending toward positive, was not statistically significant for the overall study population. However, results showed significant improvement in mortality in U.S. study participants at both doses, and in the overall population when data from both treatment arms was pooled. For more information, please see our press release.

RUXCOVID

  • In December 2020, we announced results from the RUXCOVID (NCT04362137) trial, testing ruxolitinib in patients hospitalized with severe COVID-19 but whose disease did not yet require intubation. Initial data showed that treatment with ruxolitinib plus standard-of-care (SoC) did not reduce complications in these patients with COVID-19 associated cytokine storm. For more information, please see our press release.

Questions or inquiries regarding the DEVENT study or RUXCOVID study should be made to:

U.S. Medical Information

1-888-4MED-INFO (1-855-463-3463)

medinfo@incyte.com

Supply Chain & Distribution

At present, we have ample commercial and clinical supply of our medicines to meet the needs of patients receiving our approved medicines and those participating in our global clinical trials. The global COVID-19 outbreak has not had any impact on Incyte’s supply chain to-date, and we are working diligently to increase our manufacturing efforts in response to the COVID-19 pandemic.

What is Incyte doing to ensure that its supply chain remains undisrupted? 
Close
Open

At present, we have ample commercial and clinical supply of our medicines to meet the needs of patients receiving our approved medicines and those participating in our global clinical trials. The global COVID-19 outbreak has not had any impact on Incyte’s supply chain to-date, and we are working diligently to increase our manufacturing efforts in response to the COVID-19 pandemic.

Incyte is working closely with distribution partners to monitor supply of Jakafi and ensure safeguards are in place and will work rapidly to make sure that patients continue to have access to Jakafi that has been prescribed to them.

Additionally, we have taken precautions by ensuring that our current inventory of approved and investigational medicines is stored in different locations across the United States and Europe should one specific region or warehouse face a disruption.

Community Support

Incyte is committed to supporting the local communities where we live and work, particularly during this unprecedented time of need.

Incyte has made several contributions, including:

  • Supplies, including personal protective equipment (PPE), from Incyte’s laboratories in Wilmington, DE, have been donated to local Delaware hospitals, with plans to continue providing supplies, as we are able.
  • Incyte has also donated to the Food Bank of Delaware to cover the costs of increased food distribution and pre-made weekend meal kits. 
  • Incyte Italy has made a donation to fund the purchase of hospital equipment and goods to support patients, hospitals, healthcare facilities and providers in the critically affected Lombardy region. 
  • Along with other companies, Incyte supported The Leukemia & Lymphoma Society COVID-19 Patient Financial Aid program, aimed at providing financial assistance to eligible patients for food, non-medical and other day-to-day expenses that may arise due to loss of income.

We know that needs will continue to emerge over the coming weeks and months, and we will continue to maintain close contact with our community partners and consider additional opportunities to provide support.

What is Incyte doing to prepare for and protect against the spread of COVID-19 in its offices?
Close
Open

We take the health and safety of our employees, their families and our local communities very seriously, and are closely monitoring the evolving COVID-19 pandemic. As such, we have put several measures in place to prepare for and protect against the transmission of COVID-19 in our facilities around the world and ensure we have the tools we need to support our work to serve patients. This includes:

  • Enabling those who are able to work remotely to do so.
  • Implementing additional cleanings throughout our campuses to help protect those who continue to work on site.
  • Restricting visitor access.
  • Restricting all global and domestic company air travel to trips that support essential business continuity.
  • Working closely with appropriate health authorities and fully complying with all Centers for Disease Control and Prevention (CDC), World Health Organization (WHO) and applicable local government regulations and protocols.

 

Resources

For Patients and Healthcare Professionals

For general questions please click here.

Inquiries about Incyte products or clinical trials should be directed to Incyte Medical Information:

Learn More About COVID-19

Centers for Disease Control and Prevention (CDC) Website

World Health Organization (WHO) Website

For Wholesalers and Distributors with Product/Supply Questions

In the United States email​ Incyte_TradeandDistribution@incyte.com

Outside the United States email IncyteEUSupplyChain@incyte.com

For Media

Media inquiries can be submitted here or via email at media@incyte.com

For Investors

Investor inquiries can be sent to ir@incyte.com